{"id":475,"date":"2025-02-10T14:32:43","date_gmt":"2025-02-10T14:32:43","guid":{"rendered":"https:\/\/rttrialsqa.org.uk\/?page_id=475"},"modified":"2025-02-10T14:32:43","modified_gmt":"2025-02-10T14:32:43","slug":"protis","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=475","title":{"rendered":"PROTIS"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

PROton beam Therapy (PBT) vs Intensity-modulated radiotherapy (IMRT) in Sinonasal cancer (PROTIS)<\/strong><\/h2>\n\n\n\n
Trial Summary:<\/strong><\/h5>\n\n\n\n

PROTIS is a Phase III, multicenter, randomized controlled trial comparing proton beam therapy (PBT) to photon radiotherapy (IMRT) in patients with non-metastatic sinonasal cancer. The primary objective is to determine which modality improves disease-free survival. 276 patients with sinonasal squamous cell carcinoma or adenocarcinoma, meeting specific staging criteria, will be recruited from multiple sites across the UK.<\/p>\n\n\n\n

RT QA Summary:<\/strong><\/h5>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>2 Cases<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>1 Case<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Prospective: All outlines, at least first 3 IMRT\/PBT plans
\n
\nRetrospective: All other plans<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Dosimetry <\/td>Pre-accrual Lung or Spine SABR audits<\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td>All activities<\/td>\"\"<\/td>DARS, PATHOS, TORPEdO CompARE, TORPEdO, ADePT-DDR, Nimrad<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA Contact:<\/strong> enh-tr.protisqa@nhs.net<\/a><\/p>\n\n\n\n

Chief Investigator:<\/strong> Professor David Thomson & Mr Jason Fleming<\/p>\n\n\n\n

RT Lead: <\/strong>Dr James Price<\/p>\n\n\n\n

Sponsor:<\/strong> The Christie NHS Foundation Trust<\/p>\n\n\n\n

Funder:<\/strong> Cancer Research UK (CRUK)<\/p>\n","protected":false},"excerpt":{"rendered":"

PROton beam Therapy (PBT) vs Intensity-modulated radiotherapy (IMRT) in Sinonasal cancer (PROTIS) Trial Summary: PROTIS is a Phase III, multicenter, randomized controlled […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-475","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=475"}],"version-history":[{"count":2,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/475\/revisions"}],"predecessor-version":[{"id":480,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/475\/revisions\/480"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}